Congratulations 👏 to @JLHarrington_MD on winning our 7th Annual Pecha Kucha with her fantastic presentation,PREVENT the Perfect Storm: Managing Metabolic Syndrome! #AHA25
Rise and shine, #AHA25 Come check out the Heart Failure/Cardiomyopathy Annual Pecha Kucha! ⏰8AM / 📍260-262. This year, Pecha Kucha Says: It`s All About Cardiovascular-Kidney Metabolic Health. Join us to continue the conversation on CKM as speakers contend to earn your vote! 🏆
VESALIUS-CV trial: Adding evolocumab to LLRx significantly cuts LDL-C and lowers the risk of CV death/MI/ischemic stroke/ischemia-driven revasc at 4.5 years vs. placebo in high-risk patients without a prior MI or stroke. #AHA25 View the slides here: https://t.co/DeBdHFuFb2
Diuretics in AHF:
1.loop diuretics,if refractory> 2.combine with thiazide,if refractory>
3.add dopamine,dobutamine, milrinone
4. Ultrafiltration or hemodialysis(coexist renal failure)
In case of low k+>add spironolactone
In case of alkalosis>add acetazolamide
From Braunwald
Join Dr. @AminYehyaMD and team as they shed light on the latest #epICD recommendations, examining everything from clinical trials to real-world scenarios, patient disparities, & future methodologies. Discover who could benefit most from an ICD. https://t.co/a0r5YzxGIz
#JACCHF #GDMT #HFrEF @AndrewJSauer@BiykemB@SanaAlkhatib9
In pts with HFrEF and hyperkalemia (K>5 mEq/L), sodium zirconium cyclosilicate improves optimizing the use of MRA and K levels, reduces risk of hyperkalemia and need to discontinue MRA. Slides from REALIZE-K trial presented here: https://t.co/nmi7OouSJt
Sacubitril-Valsartan effective in reducing risk of cardiotoxicity in high risk pts undergoing anthracycline chemotherapy, 18% absolute risk reduction with Sacubitril-Valsartan vs placebo. Dr. Marcely Gimenes Bonatto shares results of SARAH trial
https://t.co/HcstcCMebO
Don’t miss @noshreza battle to defend her title in the 6th Annual Pecha Kucha Heart Failure Session at #AHA24! Join us for an entertaining session on infection, inflammation, and heart failure! 🦠🫀Who will be this year’s champion?🏆 @MarkDrazner@SherylChow
In the CLEAR randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years. Full trial results: https://t.co/k3fRIyyFpd
The complexities of telehealth in heart failure management highlighted by @colleenkmac at #AHA24. We need to develop interventions to overcome systemic barriers in the digital divide.
@BidwellJT presents on a key aspect of heart failure care—the patient-provider dyad. Communication and provider trust in heart failure MATTERS and impacts patient outcomes! #AHA24
Happening now at #AHA Optimizing Heart Failure Through a Multidisciplinary approach! Learning more about international efforts to adopt GDMT from @batallah08 who established the FIRST pharmacist-led optimization clinics in the Middle East Gulf Region! #GDMTworks
Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, and hepatomegaly. Treatments are improving. Full review: https://t.co/vlStjJWraz
1 in 5 adults have an Lp(a) level that is too high. Use #CardioSmart’s Lp(a) Infographic to help patients understand this condition and how it might affect their heart. https://t.co/PIh75BxXAK #Cholesterol#ACC24
🏨 with HFrEF
Only one at a time
Go slow
Defer to outpatient
Be cautious
What is the worst that can happen?
Delay ARNI ➡️ 42% ⬆️ risk CV☠️/HF🏨
Delay BB ➡️ 25% ⬆️ risk ☠️
Delay MRA ➡️ 37% ⬆️ risk CV☠️/HF🏨
Delay SGLTi ➡️ 58% ⬆️ risk CV☠️/HF🏨/ER
Urgency needed!